Hormone substitution with premarin plus. Results of an Austrian
Wien Med Wochenschr. 1995;145(1):18-21. [Hormone substitution with premarin plus. Results of an Austrian multicenter treatment study]. [Article in German].
Generate a file for use with external citation management software.
This paper documents the results of a multicenter phase IV study, performed nationwide in Austria with 158 participating gynaecologists. A very high degree of representativeness is attributable to the high number of recruited patients. The therapy supplied was Premarin plus, containing 28 coated tablets of 0.625 or 1.25 mg conjugated estrogens and in addition 12 tablets for the last cycle days containing 5 mg medrogeston. In addition patients benefit from prophylaxis of long term even life threatening sequelae of estrogen deficiency. Objective of this phase IV study was the analysis of efficacy and safety data of a new estrogen/progestin hormone replacement therapy scheme under almost practice conditions in the gynaecological context. The results are based on the data of 1508 recruited female patients. Overall judgement of the results shows a very high level of efficacy and a well tolerated scheme of hormone replacement therapy with the option of individual estrogen dose adjustments. First of all, patients are relieved from the subjective symptoms almost fully. Thus, the dispensing gynaecologists had the option of an individual estrogen dose adjustment in case the low starting dose showed lack of efficacy. Estrogen/progestin hormone replacement therapy in menopausal women has 2 important medical rationales.
National Library of Medicine 8600 Rockville Pike, Bethesda MD, 20894 USA. National Center for Biotechnology Information, U.S.